Shook David 4

What Happened
David Shook, Chief Medical Officer of Lyell Immunopharma (LYEL), was granted a derivative award for 50,000 shares on 2026-02-10. The Form 4 reports an acquisition price of $0.00 (the filing classifies this as an award/derivative), so no cash was paid at grant. The filing does not report an immediate sale or exercise of shares.

Key Details

• Transaction date: 2026-02-10; transaction type: Grant/Award (derivative), reported 2026-02-11.
• Reported acquisition price: $0.00 (derivative award).
• Shares involved: 50,000.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Vesting (per footnote F1): 12.5% vests six months after the Vesting Commencement Date (Feb 9, 2026), then an additional 1/48th of the total shares vests monthly thereafter until fully vested, subject to continued service.
• Timeliness: Filing appears timely (Form date 2026-02-11 for a 2026-02-10 report).

Context
This is a compensation-related derivative award (likely an option or RSU-style grant) rather than an open‑market purchase or sale, so it’s primarily a personnel/compensation event—not an immediate buy/sell signal. No exercise or sale was reported with this grant. For full details (exercise price, total holdings, plan terms, and potential dilution), review the complete Form 4 and the company’s equity plan disclosures.